 |
11 Diseases |  |
3 Trials |
|
3 Trials |  |
420 News |  |
| «123 |
- ||| Enrollment closed, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - May 13, 2019
P1/2, N=382, Active, not recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting
- || Trial primary completion date: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Apr 12, 2019
P1/2, N=79, Recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2019 --> Dec 2019
- | aldoxorubicin (INNO-206) / NantWorks
Biomarker, Review, Journal: Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date. (Pubmed Central) - Apr 4, 2019
Despite the negative results from this Phase III study, the importance of anthracycline therapy in sarcoma management merits further investigation of the potential role of aldoxorubicin in this indication. Other avenues for progress include identification of sensitive histologies and biomarkers of activity, exploration of clinical niches without proven standard therapies, and exploration of alternate dosing strategies.
- | Enrollment closed: QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Nov 6, 2018
P1/2, N=173, Active, not recruiting, Sponsor: NantKwest, Inc.
Other avenues for progress include identification of sensitive histologies and biomarkers of activity, exploration of clinical niches without proven standard therapies, and exploration of alternate dosing strategies. Recruiting --> Active, not recruiting
- | Trial completion date, Trial primary completion date, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Oct 5, 2018
P1/2, N=382, Recruiting, Sponsor: NantKwest, Inc.
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2019 --> Jul 2020
- | aldoxorubicin (INNO-206) / NantWorks
Review, Journal: Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. (Pubmed Central) - Sep 19, 2018
Specifically, we highlight available data on the pharmacokinetics and efficacy from Phase I, Phase II, and Phase III trials in advanced or metastatic STS. We conclude with considerations for future directions of investigation for this promising antitumor agent.
- | Enrollment open: QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Aug 10, 2018
P1b/2, N=173, Recruiting, Sponsor: NantKwest, Inc.
We conclude with considerations for future directions of investigation for this promising antitumor agent. Not yet recruiting --> Recruiting
- | Enrollment open, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Aug 10, 2018
P1/2, N=382, Recruiting, Sponsor: NantKwest, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| New P2 trial: QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 2, 2018
P2, N=558, Not yet recruiting, Sponsor: NantKwest, Inc.
- ||||| New P2 trial, Metastases: QUILT-3.088: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Jun 19, 2018
P2, N=1064, Not yet recruiting, Sponsor: NantKwest, Inc.
- ||||| New P1/2 trial, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Jun 19, 2018
P1/2, N=382, Not yet recruiting, Sponsor: NantKwest, Inc.
- ||||| New P2 trial: QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (clinicaltrials.gov) - Jun 11, 2018
P2, N=376, Not yet recruiting, Sponsor: NantKwest, Inc.
- ||||| New P1/2 trial: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=79, Recruiting, Sponsor: NantKwest, Inc.
- ||||| New P1/2 trial: QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=173, Recruiting, Sponsor: NantKwest, Inc.
- ||||| New P1/2 trial: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=65, Recruiting, Sponsor: NantKwest, Inc.
- ||||||| aldoxorubicin (INNO-206) / ImmunityBio
Trial completion, Trial primary completion date, Metastases: Phase 3 Study to Treat Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 7, 2017
P3, N=433, Completed, Sponsor: CytRx
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2017
- | Review, Journal: Systemic Therapy for Advanced Soft Tissue Sarcoma. (Pubmed Central) - Jan 27, 2017
Newer agents such as trabectedin, eribulin, aldoxorubicin, and olaratumab have demonstrated improvements in progression-free survival, overall survival, or toxicity profiles. Future studies on treatment of advanced soft tissue sarcoma will continue to concentrate on reducing toxicity, personalization of therapy, and targeting novel pathways.
- | aldoxorubicin (INNO-206) / LadRx
Trial completion, Trial primary completion date, Surgery: Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma (clinicaltrials.gov) - Jan 6, 2017
P2, N=28, Completed, Sponsor: CytRx
Future studies on treatment of advanced soft tissue sarcoma will continue to concentrate on reducing toxicity, personalization of therapy, and targeting novel pathways. Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2016
- | aldoxorubicin (INNO-206) / ImmunityBio
Trial completion, Enrollment change: A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma (clinicaltrials.gov) - Oct 19, 2016
P2, N=16, Completed, Sponsor: CytRx
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed | N=30 --> 16
- ||| aldoxorubicin (INNO-206) / ImmunityBio
Enrollment change, Trial primary completion date, Metastases: Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 19, 2016
P1/2, N=80, Recruiting, Sponsor: CytRx
Active, not recruiting --> Completed | N=30 --> 16 N=30 --> 80 | Trial primary completion date: Dec 2016 --> Dec 2018
- | aldoxorubicin (INNO-206) / ImmunityBio
Phase classification, Metastases: Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer (clinicaltrials.gov) - Aug 19, 2016
P2b, N=132, Recruiting, Sponsor: CytRx
N=30 --> 80 | Trial primary completion date: Dec 2016 --> Dec 2018 Phase classification: P2 --> P2b
- aldoxorubicin (INNO-206) / ImmunityBio
Trial primary completion date, Metastases: Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 17, 2016
P1/2, N=30, Recruiting, Sponsor: CytRx
Phase classification: P2 --> P2b Trial primary completion date: Oct 2015 --> Dec 2016
- aldoxorubicin (INNO-206) / ImmunityBio
Enrollment closed, Phase classification, Trial primary completion date, Metastases: Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors (clinicaltrials.gov) - Aug 17, 2016
P1b, N=30, Active, not recruiting, Sponsor: CytRx
Trial primary completion date: Oct 2015 --> Dec 2016 Recruiting --> Active, not recruiting | Phase classification: P1 --> P1b | Trial primary completion date: Oct 2015 --> Dec 2016
- | aldoxorubicin (INNO-206) / LadRx
Enrollment closed, Surgery: Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma (clinicaltrials.gov) - Jan 21, 2016
P2, N=28, Active, not recruiting, Sponsor: CytRx
Recruiting --> Active, not recruiting | Phase classification: P1 --> P1b | Trial primary completion date: Oct 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- | aldoxorubicin (INNO-206) / ImmunityBio
Enrollment closed: A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma (clinicaltrials.gov) - Jan 21, 2016
P2, N=30, Active, not recruiting, Sponsor: CytRx
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| aldoxorubicin (INNO-206) / ImmunityBio
Enrollment closed, Metastases: Phase 3 Study to Treat Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jan 20, 2016
P3, N=433, Active, not recruiting, Sponsor: CytRx
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- aldoxorubicin (INNO-206) / ImmunityBio
New trial: Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy (clinicaltrials.gov) - Oct 7, 2015
P=N/A, N=0, Available, Sponsor: CytRx
- aldoxorubicin (INNO-206) / LadRx
Trial primary completion date, Surgery: Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma (clinicaltrials.gov) - Dec 19, 2014
P2, N=28, Recruiting, Sponsor: CytRx
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Dec 2015
- | aldoxorubicin (INNO-206) / ImmunityBio
Trial completion, Enrollment change, Trial primary completion date, Metastases: Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 19, 2014
P1, N=18, Completed, Sponsor: CytRx
Trial primary completion date: Mar 2015 --> Dec 2015 Active, not recruiting --> Completed | N=12 --> 18 | Trial primary completion date: Dec 2013 --> Dec 2014
- |||| aldoxorubicin (INNO-206) / ImmunityBio
Enrollment open, Metastases: Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer (clinicaltrials.gov) - Nov 3, 2014
P2, N=132, Recruiting, Sponsor: CytRx
Active, not recruiting --> Completed | N=12 --> 18 | Trial primary completion date: Dec 2013 --> Dec 2014 Not yet recruiting --> Recruiting
- | aldoxorubicin (INNO-206) / ImmunityBio
New P1/2 trial, Metastases: Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 10, 2014
P1/2, N=30, Recruiting, Sponsor: CytRx
- | aldoxorubicin (INNO-206) / ImmunityBio
New P1 trial, Metastases: Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors (clinicaltrials.gov) - Sep 10, 2014
P1, N=30, Recruiting, Sponsor: CytRx
- ||||| aldoxorubicin (INNO-206) / ImmunityBio
New P2 trial, Metastases: Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer (clinicaltrials.gov) - Jul 25, 2014
P2, N=132, Not yet recruiting, Sponsor: CytRx
- | aldoxorubicin (INNO-206) / LadRx
Trial initiation date, Surgery: Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma (clinicaltrials.gov) - May 28, 2014
P2, N=28, Recruiting, Sponsor: CytRx
Not yet recruiting --> Recruiting Initiation date: Jan 2014 --> May 2014
- | aldoxorubicin (INNO-206) / ImmunityBio
Trial completion, P1 data, Metastases: Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 17, 2014
P1, N=15, Completed, Sponsor: CytRx
Initiation date: Jan 2014 --> May 2014 Recruiting --> Completed
- |||||| aldoxorubicin (INNO-206) / ImmunityBio
Enrollment open, Metastases: Phase 3 Study to Treat Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Mar 25, 2014
P3, N=400, Recruiting, Sponsor: CytRx
Recruiting --> Completed Not yet recruiting --> Recruiting
- | aldoxorubicin (INNO-206) / ImmunityBio
Enrollment open: A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma (clinicaltrials.gov) - Mar 4, 2014
P2, N=30, Recruiting, Sponsor: CytRx
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| aldoxorubicin (INNO-206) / ImmunityBio
New P3 trial, Metastases: Phase 3 Study to Treat Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Jan 28, 2014
P3, N=400, Recruiting, Sponsor: CytRx
- | aldoxorubicin (INNO-206) / ImmunityBio
New P2 trial: A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma (clinicaltrials.gov) - Jan 5, 2014
P2, N=30, Recruiting, Sponsor: CytRx
- | aldoxorubicin (INNO-206) / LadRx
New P2 trial, Surgery: Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma (clinicaltrials.gov) - Dec 16, 2013
P2, N=28, Recruiting, Sponsor: CytRx
- ||| aldoxorubicin (INNO-206) / ImmunityBio
Enrollment closed, Metastases: Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 15, 2013
P2, N=105, Active, not recruiting, Sponsor: CytRx
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- aldoxorubicin (INNO-206) / ImmunityBio
Enrollment closed, Metastases: Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 11, 2013
P1, N=12, Active, not recruiting, Sponsor: CytRx
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | aldoxorubicin (INNO-206) / LadRx
Enrollment change, Metastases: Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer (clinicaltrials.gov) - Jun 26, 2013
P2, N=14, Completed, Sponsor: CytRx
Recruiting --> Active, not recruiting N=27 --> 14
- | aldoxorubicin (INNO-206) / LadRx
Trial completion, Metastases: Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer (clinicaltrials.gov) - Jun 26, 2013
P2, N=14, Completed, Sponsor: CytRx
N=27 --> 14 Active, not recruiting --> Completed
- | aldoxorubicin (INNO-206) / ImmunityBio
Trial completion, Metastases: Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Feb 10, 2013
P1, N=24, Completed, Sponsor: CytRx
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | aldoxorubicin (INNO-206) / ImmunityBio
New P1 trial, Metastases: Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Oct 11, 2012
P1, N=12, Active, not recruiting, Sponsor: CytRx
- | aldoxorubicin (INNO-206) / ImmunityBio
New P1 trial, P1 data, Metastases: Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 26, 2012
P1, N=15, Completed, Sponsor: CytRx
- | aldoxorubicin (INNO-206) / LadRx
New P2 trial, Metastases: Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 17, 2012
P2, N=14, Completed, Sponsor: CytRx
- aldoxorubicin (INNO-206) / ImmunityBio
Trial withdrawal: INNO-206 in Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Feb 7, 2012
P2, N=0, Withdrawn, Sponsor: CytRx
Active, not recruiting --> Completed Terminated --> Withdrawn
- ||||| aldoxorubicin (INNO-206) / ImmunityBio
New P2 trial, Metastases: Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 19, 2012
P2, N=105, Active, not recruiting, Sponsor: CytRx